Bio-TechneMEX:TECH 83 Return-on-Tangible-Asset is 16.61% as of Mar. 2026, which is 19% below its 10-year median of 20.58. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,109.72. The stock has 8 warning signs investors should review. Among 1,416 Biotechnology companies, Bio-Techne ranks better than 91.03% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bio-Techne's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN3,682 Mil. Bio-Techne's average total tangible assets for the quarter that ended in Mar. 2026 was MXN22,172 Mil. Therefore, Bio-Techne's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 16.61%.
The historical rank and industry rank for Bio-Techne's Return-on-Tangible-Asset or its related term are showing as below:
MEX:TECH'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.03 Med: 20.58 Max: 33.84
Current: 8.98
During the past 13 years, Bio-Techne's highest Return-on-Tangible-Asset was 33.84%. The lowest was 6.03%. And the median was 20.58%.
MEX:TECH's Return-on-Tangible-Asset is ranked better than 91.03% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs MEX:TECH: 8.98
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bio-Techne Return-on-Tangible-Asset Related Terms
Bio-Techne Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs ARWR, CYTK, KRYS: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Bio-Techne's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.61% mean?
Bio-Techne (MEX:TECH) has a Return-on-Tangible-Asset of 16.61% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bio-Techne and its competitors. This is 19% below median its historical median of 20.58. Over the past decade, Bio-Techne's Return-on-Tangible-Asset has ranged from 6.03 to 33.84. According to the industry distribution chart, Bio-Techne ranks #127 out of 1416 companies in the Biotechnology industry, placing it in the top 9%.
Is Bio-Techne's Return-on-Tangible-Asset too high?
Bio-Techne's current Return-on-Tangible-Asset of 16.61% is 19% below median its 10-year median of 20.58. Over the past 10 years, this metric has ranged from a low of 6.03 to a high of 33.84. Based on the distribution chart, Bio-Techne ranks #127 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Return-on-Tangible-Asset compare to ARWR and CYTK?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #127 out of 1416 companies for Return-on-Tangible-Asset. This places Bio-Techne in the top 9% of its industry — outperforming the majority of peers. Historically, Bio-Techne's own Return-on-Tangible-Asset has ranged from 6.03 to 33.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bio-Techne and its competitors. Bio-Techne's current Return-on-Tangible-Asset is 16.61%, which is 19% below median its own 10-year median of 20.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Return-on-Tangible-Asset of 16.61%. The stock's GF Value™ is MXN1,109.72, compared to a current price of MXN1,090.00 — trading 1.8% below its estimated fair value. The current Return-on-Tangible-Asset is 16.61%, which is 19% below median its 10-year median of 20.58. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Return-on-Tangible-Asset is 16.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 1.8% below its estimated GF Value™ of MXN1,109.72.
Key valuation signals for MEX:TECH:
Return-on-Tangible-Asset: 16.61% (19% below median its 10-year median of 20.58)
GF Value™: MXN1,109.72 vs. price of MXN1,090.00 (1.8% below fair value)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
